Prognostic analysis reports the value of immune-nutritional indexes in glioblastoma patients, highlighting potential improvements in two-year mortality prediction.
Background: Glioblastoma (GBM) is the poorest prognosis for a malignant brain tumor; however, postoperative chemoradiotherapy has been reported to improve survival time. Therefore, high-cost treatment for prolonged survival time led to health, economic burden, and catastrophic costs in a limited-resource setting. Various immune-nutritional indexes can indicate patient status; both nutritional and inflammatory status may help predict prognosis. The primary objective was to evaluate the prognostication of immune-nutritional indexes in GBM patients. Moreover, the secondary objective was to compare how well clinical nomograms with and without immune-nutritional indexes predicted 2-year mortality.
No takes yet. Share an insight, caveat, or question.
Tunthanathip et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: